Catridecacog

Catridecacog (brand name Tretten in the US and NovoThirteen in Europe[1]) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.[2] It was brought to market by Novo Nordisk.[1]

Catridecacog
Clinical data
Trade namesTretten, NovoThirteen
AHFS/Drugs.comtretten
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Injection
    ATC code
    Legal status
    Legal status
    Identifiers
    ChemSpider
    • none
    KEGG

    References
    1. NHS New Drugs Online Report for catridecacog Page accessed July 2, 2015
    2. Catridecacog: First drug to treat rare genetic blood clotting disorder. The Pharmacist February 01, 2014
    • Korte W (9 July 2014). "Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?". J Blood Med. 5: 107–13. doi:10.2147/JBM.S35395. PMC 4096448. PMID 25031548.
    • Mozaffari S, Nikfar S, Abdollahi M (July 2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835. CNDO-210 and Catridecacog were discontinued due to safety concerns and lack of efficacy, respectively.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.